Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Kensey Nash matrix tech

This article was originally published in Clinica

Executive Summary

Kensey Nash has received US 510(k) clearance for its second extracellular matrix (ECM), the Meso BioMatrix. The approval allows the porcine-based mesothelium ECM to be used in general surgery for the reinforcement and repair of soft tissue, including hernia repair, plastic and reconstructive surgery and urologic, gynaecologic and gastroenterological procedures. Exton, Pennsylvania-based Kensey Nash said that it is currently seeking partners to take the Meso BioMatrix into the urogynaecology, wound care and orthopaedic markets. The company’s first ECM was the Medeor product, a dermal matrix which received FDA 510(k) approval in November 2009.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094801

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel